Relieves bronchospasm. ANDA 211888, held by Luoxin Aurovitas. Albuterol Sulfate.
As of Nov 16, 2026, ANDA 211888 (Albuterol Sulfate), held by Luoxin Aurovitas, was first approved by FDA on Apr 20, 2020, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 20, 2020 | Original application | Approved | None posted |
| Albuterol SulfateEQ 0.021% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| Albuterol SulfateEQ 0.042% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| Jun 23, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 20, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters